Abstract:Background There is currently a lack of model for predicting the occurrence of venous thromboembolism (VTE) in patients with lung cancer. Machine learning (ML) techniques are being increasingly adapted for use in the medical field because of their capabilities of intelligent analysis and scalability. This study aimed to develop and validate ML models to predict the incidence of VTE among lung cancer patients. Methods Data of lung cancer patients from a Grade 3A cancer hospital in China with and without VTE were included. Patient characteristics and clinical predictors related to VTE were collected. The primary endpoint was the diagnosis of VTE during index hospitalization. We calculated and compared the area under the receiver operating characteristic curve (AUROC) using the selected best-performed model (Random Forest model) through multiple model comparison, as well as investigated feature contributions during the training process with both permutation importance scores and the impurity-based feature importance scores in random forest model. Results In total, 3,398 patients were included in our study, 125 of whom experienced VTE during their hospital stay. The ROC curve and precision–recall curve (PRC) for Random Forest Model showed an AUROC of 0.91 (95% CI : 0.893–0.926) and an AUPRC of 0.43 (95% CI : 0.363–0.500). For the simplified model, five most relevant features were selected: Karnofsky Performance Status (KPS), a history of VTE, recombinant human endostatin, EGFR-TKI, and platelet count. We re-trained a random forest classifier with results of the AUROC of 0.87 (95% CI : 0.802–0.917) and AUPRC of 0.30 (95% CI : 0.265–0.358), respectively. Conclusion According to the study results, there was no conspicuous decrease in the model’s performance when use fewer features to predict, we concluded that our simplified model would be more applicable in real-life clinical settings. The developed model using ML algorithms in our study has the potential to improve the early detection and prediction of the incidence of VTE in patients with lung cancer.

Risk Prediction of Malignant Tumor Related Venous Thrombosis

[Tissue factors and venous thromboembolism in cancer patients].

Prediction and Preventive Medication of Venous Thromboembolism in Patients with Cancer

Establishment and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Based on a Meta-Analysis

Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Patients Using Machine Learning

Research progress on venous thrombosis development in patients with malignant tumors

Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

AI-based Prediction of Catheter-related Thrombosis Risk for Cancer Patients.

A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer

Venous thromboembolism in non-small-cell lung cancer patients:Report of 15 cases

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Prevention of tumor-related venous thromboembolism

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis in Cancer Patients.

Development and validation of a predictive risk tool for VTE in women with breast cancer under chemotherapy: a cohort study in China

Advances in Cancer Related Venous Thromboembolism Research

Machine learning models for prediction of postoperative venous thromboembolism in gynecological malignant tumor patients

Prevention of cancer-related venous thromboembolism

Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer

Machine Learning Predicts Cancer-Associated Deep Vein Thrombosis Using Clinically Available Variables

Predicting the occurrence of venous thromboembolism: construction and verification of risk warning model

Novel risk prediction models, involving coagulation, thromboelastography, stress response, and immune function indicators, for deep vein thrombosis after radical resection of cervical cancer and ovarian cancer